Pembrolizumab and nivolumab are ICIs targeting programmed cell death protein 1 and have both been approved by the U.S. Food and Drug Administration for the treatment of microsatellite instability-high/DNA mismatch repair-deficient CRC (5, 6). The gene discussed is PDCD1; the disease is colorectal carcinoma.